Mészáros Balázs, Veres Dániel Sándor, Nagyistók Luca, Somogyi Anikó, Rosta Klára, Herold Zoltán, Kukor Zoltán, Valent Sándor
Department of Obstetrics and Gynecology, Semmelweis University, Budapest, Hungary.
Department of Biophysics and Radiation Biology, Semmelweis University, Budapest, Hungary.
Front Med (Lausanne). 2023 Jan 13;9:1076372. doi: 10.3389/fmed.2022.1076372. eCollection 2022.
To review of the efficacy and safety of pravastatin use for prophylaxis and treatment of preeclampsia.
Systematic review and meta-analysis of clinical studies evaluating pravastatin for treatment and/or prophylaxis of preeclampsia.
Two independent reviewers systematically searched data from PubMed, Scopus, Web of Science, Cochrane, Embase, and clinicaltrials.gov databases, for studies evaluating pravastatin for prevention of pre-eclampsia.
Fourteen studies were identified, including 1,570 pregnant women who received either pravastatin or placebo, published between 2003 and 2022. From these studies, 5 studies were identified for inclusion in the meta-analysis to evaluate the role of pravastatin use prior to 20 weeks of gestation, to prevent pre-eclampsia, Pravastatin treatment reduced the incidence of preeclampsia by 61% and premature birth by 45%. Among the newborns, there was a 45% reduction in intrauterine growth retardation (IUGR) in the treated group, as well as a 77% reduction in those receiving neonatal intensive care unit (NICU) admissions.
Prophylactic treatment with pravastatin appears to reduce risk of developing pre-eclampsia as well as potentially lowering risk of IUGR, preterm birth, and NICU admission in neonates.
回顾普伐他汀用于预防和治疗子痫前期的疗效和安全性。
对评估普伐他汀治疗和/或预防子痫前期的临床研究进行系统评价和荟萃分析。
两名独立的评审员系统地检索了来自PubMed、Scopus、科学网、Cochrane、Embase和clinicaltrials.gov数据库的数据，以查找评估普伐他汀预防子痫前期的研究。
共确定了14项研究，包括1570名接受普伐他汀或安慰剂治疗的孕妇，这些研究发表于2003年至2022年之间。从这些研究中，确定了5项研究纳入荟萃分析，以评估妊娠20周前使用普伐他汀预防子痫前期的作用。普伐他汀治疗使子痫前期的发生率降低了61%，早产率降低了45%。在新生儿中，治疗组的宫内生长受限（IUGR）减少了45%，入住新生儿重症监护病房（NICU）的新生儿减少了77%。
普伐他汀预防性治疗似乎可降低子痫前期的发生风险，并可能降低新生儿IUGR、早产和入住NICU的风险。
